Does malaria suffer from lack of memory?

Immunological Reviews

Volumn 201, Issue , 2004, Pages 268-290

  Struik, Siske S ^a   Riley, Eleanor M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MALARIA VACCINE;

APOPTOSIS; B LYMPHOCYTE; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFECTION RISK; LIFE CYCLE; LONG TERM MEMORY; MALARIA; PRIORITY JOURNAL; REINFECTION; REVIEW; T LYMPHOCYTE; VACCINATION;

ANIMALS; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNITY, NATURAL; IMMUNOLOGIC MEMORY; INFANT; INFANT, NEWBORN; MALARIA VACCINES; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 4844223378     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2004.00181.x     Document Type: Review

References (187)

1. Andre FE. Vaccinology: past achievements, present roadblocks and future promises. Vaccine 2003;21:593-595.
2. Artavanis-Tsakonas K, Tongren JE, Riley EM. The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin Exp Immunol 2003;133:145-152.
3. Maizels RM, Yazdanbakhsh M. Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat Rev Immunol 2003;3:733-744.
4. Korenromp EL, Williams BG, Gouws E, Dye C, Snow RW. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis 2003;3:349-358.
5. Lengeler C, Armstrong-Schellenberg J, D'Alessandro U, Binka F, Cattani J. Relative versus absolute risk of dying reduction after using insecticide-treated nets for malaria control in Africa. Trop Med Int Health 1998;3:286-290.
6. Snow RW, Craig M, Deichmann U, Marsh K. Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull World Health Organ 1999;77:624-640.
7. Goodman CA, Mills AJ. The evidence base on the cost-effectiveness of malaria control measures in Africa. Health Policy Plan 1999;14:301-312.
8. Lengeler C. Insecticide treated bed nets and curtains for malaria control. Infectious diseases module of the Cochrane database of systematic reviews - The Cochrane library. 1998.
9. Moorthy VS, Good MF, Hill AV. Malaria vaccine developments. Lancet 2004;363:150-156.
10. Hoffman SL. Malaria vaccine development. Rockville MD, USA: Blackwell Publishing, 1996.
11. Good MF. Towards a blood-stage vaccine for malaria: are we following all the leads? Nat Rev Immunol 2001;1:117-125.
12. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 1973;266:169-177.
13. Nardin E, Zavala F, Nussenzweig V, Nussenzweig RS. Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials. Parassitologia 1999;41:397-402.
14. Webster D, Hill AV. Progress with new malaria vaccines. Bull World Health Organ 2003;81:902-909.
15. Good MF, et al. Limited immunological recognition of critical malaria vaccine candidate antigens. Science 1988;242:574-577.
16. Carter R, Graves PM, Quakyi IA, Good MF. Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies. J Exp Med 1989;169:135-147.
17. Taylor RR, et al. Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Int Immunol 1996;8:905-915.
18. Graves P, Gelband H. Vaccines for preventing malaria. Cochrane Database Syst Rev 2000:CD000129.
19. Dunachie SJ, Hill AV. Prime-boost strategies for malaria vaccine development. J Exp Biol 2003;206:3771-3779.
20. Bruce-Chwatt LJ. A longitudinal survey of natural malaria infection in a group of West African adults. West Afr J Med 1963;12:199-217.
21. Kwiatkowski D. The molecular genetic approach to malarial pathogenesis and immunity. Parassitologia 1999;41:233-240.
22. Riley EM. Is T-cell priming required for initiation of pathology in malaria infections? Immunol Today 1999;20:228-233.
23. Stevenson MM, Riley EM. Innate immunity to malaria. Nat Rev Immunol 2004;4:169-180.
24. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-305.
25. Taylor RR, Smith DB, Robinson VJ, McBride JS, Riley EM. Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun 1995;63:4382-4388.
26. Drakeley CJ, Mulder L, Tchuinkam T, Gupta S, Sauerwein R, Targett GA. Transmission-blocking effects of sera from malaria-exposed individuals on Plasmodium falciparum isolates from gametocyte carriers. Parasitology 1998;116:417-423.
27. Healer J, McGuinness D, Carter R, Riley E. Transmission-blocking immunity to Plasmodium falciparum in malaria-immune individuals is associated with antibodies to the gamete surface protein Pfs230. Parasitology 1999;119:425-433.
28. Ong CS, et al. The primary antibody response of malaria patients to Plasmodium falciparum sexual stage antigens which are potential transmission blocking vaccine candidates. Parasite Immunol 1990;12:447-456.
29. Druilhe P. A hypothesis about the chronicity of malaria infection. Parasitol Today 1997;13:353-357.
30. Snow RW, Marsh K. The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol 2002;52:235-264.
31. Duffy PE, Fried M. Malaria during pregnancy: parasites, antibodies and chondroitin sulphate A. Biochem Soc Trans 1999;27:478-482.
32. Cot M, Deloron P. [Malaria during pregnancy: consequences and interventional perspectives]. Med Trop (Mars) 2003;63:369-380.
33. Gill G. Some points in the epidemiology of malaria arising out of the study of the malaria epidemic in Ceylon in 1934-35. Trans R Soc Trop Med Hyg 1936;29:427-480.
34. Bastien P. Particularites epidemiologiques des acces pernicieux a plasmodium faciparum dans un contexte d'epidemie palustre. Vanuatu 1975-85. Med Trop (Mars) 1987;47:125-131.
35. Zhou G, Minakawa N, Githeko AK, Yan G. Association between climate variability and malaria epidemics in the East African highlands. Proc Natl Acad Sci USA 2004;101:2375-2380.
36. Rowland M, Nosten F. Malaria epidemiology and control in refugee camps and complex emergencies. Ann Trop Med Parasitol 2001;95:741-754.
37. Baird JK, et al. Onset of clinical immunity to Plasmodium falciparum among Javanese migrants to Indonesian Papua. Ann Trop Med Parasitol 2003;97:557-564.
38. Collins WE, Jeffery GM. A retrospective examination of secondary sporozoite- and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic and clinical immunity following secondary infection. Am J Trop Med Hyg 1999;61:20-35.
39. Collins WE, Jeffery GM. A retrospective examination of sporozoite- and trophozoite-induced infections with Plasmodium falciparum in patients previously infected with heterologous species of Plasmodium: effect on development of parasitologic and clinical immunity. Am J Trop Med Hyg 1999;61:36-43.
40. Smith TA, Leuenberger R, Lengeler C. Child mortality and malaria transmission intensity in Africa. Trends Parasitol 2001;17:145-149.
41. Kinyanjui SM, Bull P, Newbold CI, Marsh K. Kinetics of antibody responses to Plasmodium falciparum-infected erythrocyte variant surface antigens. J Infect Dis 2003;187:667-674.
42. Lalloo DG, et al. Severe and complicated falciparum malaria in Melanesian adults in Papua New Guinea. Am J Trop Med Hyg 1996;55:119-124.
43. Kleinschmidt I, Sharp B. Patterns in age-specific malaria incidence in a population exposed to low levels of malaria transmission intensity. Trop Med Int Health 2001;6:986-991.
44. Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ. The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg 1997;91:256-262.
45. Gupta S, Snow RW, Donnelly CA, Marsh K, Newbold C. Immunity to non-cerebral severe malaria is acquired after one or two infections. Nat Med 1999;5:340-343.
46. Hviid L, Staalsoe T. Malaria immunity in infants: a special case of a general phenomenon? Trends Parasitol 2004;20:66-72.
47. Bendixen M, Msangeni HA, Pedersen BV, Shayo D, Bodker R. Diversity of Plasmodium falciparum populations and complexity of infections in relation to transmission intensity and host age: a study from the Usambara Mountains. Tanzania Trans R Soc Trop Med Hyg 2001;95:143-148.
48. Gupta S, Snow RW, Donnelly C, Newbold C. Acquired immunity and postnatal clinical protection in childhood cerebral malaria. Proc R Soc Lond B Biol Sci 1999;266:33-38.
49. Baird JK. Host age as a determinant of naturally acquired immunity to Plasmodium falciparum. Parasitol Today 1995;11:105-111.
50. Rogier C, Commenges D, Trape JF. Evidence for an age-dependent pyrogenic threshold of Plasmodium falciparum parasitemia in highly endemic populations. Am J Trop Med Hyg 1996;54:613-619.
51. McGuinness D, Koram K, Bennett S, Wagner G, Nkrumah F, Riley E. Clinical case definitions for malaria: clinical malaria associated with very low parasite densities in African infants. Trans R Soc Trop Med Hyg 1998;92:527-531.
52. Smith T, Schellenberg JA, Hayes R. Attributable fraction estimates and case definitions for malaria in endemic areas. Stat Med 1994;13:2345-2358.
53. McGregor IA, Wilson RJM. Principles and Practice of Malariology. Edinburgh: Churchill livingstone 1986.
54. Matteelli A, Colombini P, Gulletta M, Castelli F, Carosi G. Epidemiological features and case management practices of imported malaria in northern Italy 1991-95. Trop Med Int Health 1999;4:653-657.
55. Jelinek T, et al. Imported Falciparum malaria in Europe: sentinel surveillance data from the European network on surveillance of imported infectious diseases. Clin Infect Dis 2002;34:572-576.
56. Di Perri G, et al. West African immigrants and new patterns of malaria imported to North Eastern Italy. J Travel Med 1994;1:147-151.
57. Deloron P, Chougnet C. Is immunity to malaria really short lived. Parasitol Today 1992;8:375-378.
58. Gandon S, Mackinnon MJ, Nee S, Read AF. Imperfect vaccines and the evolution of pathogen virulence. Nature 2001;414:751-756.
59. Gandon S, Mackinnon M, Nee S, Read A. Imperfect vaccination: some epidemiological and evolutionary consequences. Proc R Soc Lond B Biol Sci 2003;270:1129-1136.
60. Gozar MM, Muratova O, Keister DB, Kensil CR, Price VL, Kaslow DC. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate. Exp Parasitol 2001;97:61-69.
61. Hisaeda H, et al. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block die ability of Plasmodium vivax to infect mosquitoes. Infect Immun 2000;68:6618-6623.
62. Drakeley CJ, Akim NI, Sauerwein RW, Greenwood BM, Targett GA. Estimates of die infectious reservoir of Plasmodium falciparum malaria in The Gambia and in Tanzania. Trans R Soc Trop Med Hyg 2000;94:472-476.
63. Drakeley CJ, Flobbe K, Greenwood BM, Targett GA. Plasmodium falciparum gametocytes in Gambian adults. Ann Trop Med Parasitol 2000;94:399-401.
64. Urban BC, Roberts DJ. Inhibition of T cell function during malaria: implications for immunology and vaccinology. J Exp Med 2003;197:137-141.
65. Bell D. Lecture notes on Tropical Medicine, 1995.
66. Lepers JP, Deloron P, Fontenille D, Coulanges P. Reappearance of falciparum malaria in central highland plateau of Madagascar. Lancet 1988;1:586.
67. Romi R, et al. Impact of the malaria control campaign (1993-98) in the highlands of Madagascar: parasitological and entomological data. Am J Trop Med Hyg 2002;66:2-6.
68. Contamin H, et al. Different genetic characteristics of Plasmodium falciparum isolates collected during successive clinical malaria episodes in Senegalese children. Am J Trop Med Hyg 1996;54:632-643.
69. Roper C, et al. Detection of very low level Plasmodium falciparum infections using the nested polymerase chain reaction and a reassessment of die epidemiology of unstable malaria in Sudan. Am J Trop Med Hyg 1996;54:325-331.
70. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K. Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med 1998;4:358-360.
71. Rijkers GT, Sanders EA, Breukels MA, Zegers BJ. Infant B cell responses to polysaccharide determinants. Vaccine 1998;16:1396-1400.
72. Siegrist CA. Neonatal and early life vaccinology. Vaccine 2001;19:3331-3346.
73. Zinkernagel RM. On natural and artificial vaccinations. Annu Rev Immunol 2003;21:515-546.
74. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995;182:409-418.
75. Taylor RR, Allen SJ, Greenwood BM, Riley EM. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg 1998;58:406-413.
76. O'Donnell RA, et al. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med 2001;193:1403-1412.
77. Okech BA, et al. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1 (19), predicts protection from malaria infection and high-density parasitemia. Infect Immun 2004;72:1557-1567.
78. Langhome J, Simon-Haarhaus B. Differential T cell responses to Plasmodium chabaudi chabaudi in peripheral blood and spleens of C57BL/6 mice during infection. J Immunol 1991;146:2771-2775.
79. Helmby H, Jonsson G, Troye-Blomberg M. Cellular changes and apoptosis in the spleens and peripheral blood of mice infected with blood-stage Plasmodium chabaudi chabaudi AS. Infect Immun 2000;68:1485-1490.
80. Riley EM, Andersson G, Otoo LN, Jepsen S, Greenwood BM. Cellular immune responses to Plasmodium falciparum antigens in Gambian children during and after an acute attack of falciparum malaria. Clin Exp Immunol 1988;73:17-22.
81. Hviid L, et al. Loss of cellular immune reactivity during acute Plasmodium falciparum malaria. FEMS Microbiol Immunol 1991;3:219-227.
82. Hviid L, Theander TG, Abdulhadi NH, Abu-Zeid YA, Bayoumi RA, Jensen JB. Transient depletion of T cells with high LFA-1 expression from peripheral circulation during acute Plasmodium falciparum malaria. Eur J Immunol 1991;21:1249-1253.
83. Hviid L, Kurtzhals JA, Goka BQ, Oliver-Commey JO, Nkrumah FK, Theander TG. Rapid reemergence of T cells into peripheral circulation following treatment of severe and uncomplicated Plasmodium falciparum malaria. Infect Immun 1997;65:4090-4093.
84. Black GF, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002;359:1393-1401.
85. Struik SS, Omer FM, Artavanis-Tsakonas K, Riley EM. Uninfected erythrocytes inhibit Plasmodium falciparum-induced cellular immune responses in whole blood assays. Blood 2004;103:3084-3092.
86. Artavanis-Tsakonas K, Riley EM. Innate immune response to malaria: Rapid induction of IFN-gamma from human NK cells by live Plasmodium falciparum-infected erythrocytes. J Immunol 2002;169:2956-2963.
87. Waterfall M, Black A, Riley E. Gammadelta+ T cells preferentially respond to live rather than killed malaria parasites. Infect Immun 1998;66:2393-2398.
88. Zevering Y, et al. High frequency of malaria-specific T cells in non-exposed humans. Eur J Immunol 1992;22:689-696.
89. Jones KR, Hickling JK, Targett GA, Playfair JH. Polyclonal in vitro proliferative responses from nonimmune donors to Plasmodium falciparum malaria antigens require UCHL1+ (memory) T cells. Eur J Immunol 1990;20:307-315.
90. + T cells from non-exposed donors: potential for cross-reactive memory T cells to cause disease. Int Immunol 1995;7:821-833.
91. + T cell responses common to Plasmodium falciparum and recall antigens. Int Immunol 1997;9:1857-1865.
92. Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, Selin LK. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol 2002;3:627-634.
93. Smith DK, Dudani R, Pedras-Vasconcelos JA, Chapdelaine Y, van Faassen H, Sad S. Cross-reactive antigen is required to prevent erosion of established T cell memory and tumor immunity: a heterologous bacterial model of attrition. J Immunol 2002;169:1197-1206.
94. Traggiai E, Puzone R, Lanzavecchia A. Antigen dependent and independent mechanisms that sustain serum antibody levels. Vaccine 2003;21:S35-S37.
95. Riley EM, Morris-Jones S, Blackman MJ, Greenwood BM, Holder AA. A longitudinal study of naturally acquired cellular and humoral Immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. Parasite Immunol 1993;15:513-524.
96. Flanagan KL, et al. Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assays. J Immunol 2001;167:4729-4737.
97. Troye-Blomberg M, et al. T and B cell responses of Plasmodium falciparum malaria-immune individuals to synthetic peptides corresponding to sequences in different regions of the P. falciparum antigen Pf155/ RESA. J Immunol 1989;143:3043-3048.
98. Troye-Blomberg M, et al. Production by activated human T cells of interleukin 4 but not interferon-gamma is associated with elevated levels of serum antibodies to activating malaria antigens. Proc Natl Acad Sci USA 1990;87:5484-5488.
99. Diallo TO, Nguer CM, Dieye A, Spiegel A, Perraut R, Garraud O. Immune responses to Plasmodium falciparum-MSP1 antigen: lack of correlation between antibody responses and the capacity of peripheral cellular immune effectors to respond to this antigen in vitro. Immunol Lett 1999;67:217-221.
100. Riley EM, Jobe O, Blackman M, Whittle HC, Greenwood BM. Plasmodium falciparum schizont sonic extracts suppress lymphoproliferative responses to mitogens and antigens in malaria-immune adults. Infect Immun 1989;57:3181-3188.
101. Riley EM, Morris-Jones S, Taylor-Robinson AW, Holder AA. Lymphoproliferative responses to a merozoite surface antigen of Plasmodium falciparum: preliminary evidence for seasonal activation of CD8+/HLA-DQ- restricted suppressor cells. Clin Exp Immunol 1993;94:64-67.
102. Theander TG. Activation of CD8-positive suppressor cells during the malaria season. Immunol Infect Dis 1993;3:97-102.
103. Rhee MS, Akanmori BD, Waterfall M, Riley EM. Changes in cytokine production associated with acquired immunity to Plasmodium falciparum malaria. Clin Exp Immunol 2001;126:503-510.
104. Omer FM, Riley EM. Transforming growth factor beta production is inversely correlated with severity of murine malaria infection. J Exp Med 1998;188:39-48.
105. Li C, Sanni LA, Omer F, Riley E, Langhome J. Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient mice are ameliorated by anti-tumor necrosis factor alpha and exacerbated by anti-transforming growth factor beta antibodies. Infect Immun 2003;71:4850-4856.
106. Read S, Powrie F. CD4(+) Regulatory T Cells. Curr Opin Immunol 2001;13:644-649.
107. McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol 2002;110:693-702.
108. Sinnis P, Nardin E. Sporozoite antigens: biology and immunology of the circumsporozoite protein and thrombospondin-related anonymous protein. Chem Immunol 2002;80:70-96.
109. Hoffman SL, et al. Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science 1987;237:639-642.
110. Riley EM, et al. Recognition of dominant T cell-stimulating epitopes from the circumsporozoite protein of Plasmodium falciparum and relationship to malaria morbidity in Gambian children. Trans R Soc Trop Med Hyg 1990;84:648-657.
111. Stoute JA, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997;336:86-91.
112. Pinder M, et al. Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia. Clin Exp Immunol 2004;135:286-293.
113. Saul A. Kinetic constraints on the development of a malaria vaccine. Parasite Immunol 1987;9:1-9.
114. Nardin EH, Nussenzweig RS, McGregor IA, Bryan JH. Antibodies to sporozoites: their frequent occurrence in individuals living in an area of hyperendemic malaria. Science 1979;206:597-599.
115. Miller KD, et al. Early acquisition of antibody to Plasmodium falciparum sporozoites in nonimmune temporary residents of Africa. J Infect Dis 1988;158:868-871.
116. Webster HK, et al. Circumsporozoite antibody as a serologic marker of Plasmodium falciparum transmission. Am J Trop Med Hyg 1992;47:489-497.
117. Ramasamy R, Nagendran K, Ramasamy MS. Antibodies to epitopes on merozoite and sporozoite surface antigens as serologic markers of malaria transmission: studies at a site in the dry zone of Sri Lanka. Am J Trop Med Hyg 1994;50:537-547.
118. Webster HK, Boudreau EF, Pang LW, Permpanich B, Sookto P, Wirtz RA. Development of immunity in natural Plasmodium falciparum malaria: antibodies to the falciparum sporozoite vaccine 1 antigen (R32tet32). J Clin Microbiol 1987;25:1002-1008.
119. Gray D. A role for antigen in the maintenance of immunological memory. Nat Rev Immunol 2002;2:60-65.
120. Fontes CJ, Bathurst I, Krettli AU. Plasmodium vivax sporozoite antibodies in individuals exposed during a single malaria outbreak in a non-endemic area. Am J Trop Med Hyg 1991;44:28-33.
121. Braga EM, Fontes CJ, Krettli AU. Persistence of humoral response against sporozoite and blood-stage malaria antigens 7 years after a brief exposure to Plasmodium vivox. J Infect Dis 1998;177:1132-1135.
122. Chougnet C, et al. Humoral and cell-mediated immune responses to the Plasmodium falciparum antigens PF155/RESA and CS protein: seasonal variations in a population recently reexposed to endemic malaria. Am J Trop Med Hyg 1990;43:234-242.
123. Tsuji M, Zavala F. T cells as mediators of protective immunity against liver stages of Plasmodium. Trends Parasitol 2003;19:88-93.
124. Huffman SL, et al. Human lymphocyte proliferative response to a sporozoite T cell epitope correlates with resistance to falciparum malaria. J Immunol 1989;142:1299-1303.
125. Good MF, et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci USA 1988;85:1199-1203.
126. Reece WH, et al. A CD4(+) T-cell immune response to a conserved epitope in die circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 2004;10:406-410.
127. Lalvani A, Hill AV. Cytotoxic T-lymphocytes against malaria and tuberculosis: from natural immunity to vaccine design. Clin Sci (Lond) 1998;95:531-538.
128. Plebanski M, Aidoo M, Whittle HC, Hill AV. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. J Immunol 1997;158:2849-2855.
129. Sinden RE, Gilles HM. The Malaria Parasites. In: Warrell DA, Gilles HM, eds. Essential Malariology, 4th edn. London: Arnold, 2002: 8-34.
130. Hoffman SL, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002;185:1155-1164.
131. Bojang KA, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001;358:1927-1934.
132. Lee EA, et al. Induction of T helper type 1 and 2 responses to 19-kilodalton merozoite surface protein 1 in vaccinated healthy volunteers and adults naturally exposed to malaria. Infect Immun 2002;70:1417-1421.
133. Hafalla JC, Sano G, Carvalho LH, Morrot A, Zavala F. Short-term antigen presentation and single clonal burst limit the magnitude of the CD8(+) T cell responses to malaria liver stages. Proc Natl Acad Sci USA 2002;99:11819-11824.
134. Gilbert SC, et al. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 1998;279:1173-1177.
135. Plebanski M, et al. Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming. Nat Med 1999;5:565-571.
136. Crispe IN. Hepatic T cells and liver tolerance. Nat Rev Immunol 2003;3:51-62.
137. Dennert G. Elimination of virus-specific cytotoxic T cells in the liver. Crit Rev Immunol 2002;22:1-11.
138. Migot F, Chougnet C, Raharimalala L, Astagneau P, Lepers JP, Deloron P. Human immune responses to the Plasmodium falciparum ring-infected erythrocyte surface antigen (Pf155/RESA) after a decrease in malaria transmission in Madagascar. Am J Trop Med Hyg 1993;48:432-439.
139. Chougnet C, Henzel D, Diakhate L, Imbert P, Bouchaud O, Deloron P. Quantification of T cells reactive to Pf155/RESA peptides in Plasmodium falciparum-exposed individuals. Res Immunol 1994;145:257-266.
140. Kabilan L, et al. Number of cells from Plamodium falciparum-immune donors that produce gamma interferon in vitro in response to Pf155/RESA, a malaria vaccine candidate antigen. Infect Immun 1990;58:2989-2994.
141. Giha HA, et al. The epidemiology of febrile malaria episodes in an area of unstable and seasonal transmission. Trans R Soc Trop Med Hyg 2000;94:645-651.
142. Hviid L, et al. Cell-mediated immune responses to soluble Plasmodium falciparum antigens in residents from an area of unstable malaria transmission in the Sudan. APMIS 1990;98:594-604.
143. Wen L, Hanvanich M, Werner-Favre C, Brouwers N, Perrin LH, Zubler RH. Limiting dilution assay for human B cells based on their activation by mutant EL4 thymoma cells: total and antimalaria responder B cell frequencies. Eur J Immunol 1987;17:887-892.
144. Cornille-Brogger R, Mathews HM, Storey J, Ashkar TS, Brogger S, Molineaux L. Changing patterns in the humoral immune response to malaria before, during, and after the application of control measures: a longitudinal study in the West African savanna. Bull World Health Organ 1978;56:579-600.
145. Molineaux L, Cornille-Brogger R, Mathews HM, Storey J. Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bull World Health Organ 1978;56:573-578.
146. Vande Waa JA, Jensen JE, Akood MA, Bayoumi R. Longitudinal study on the in vitro immune response to Plasmodium falciparum in Sudan. Infect Immun 1984;45:505-510.
147. Ferreira MU, Kimura EA, De Souza JM, Katzin AM. The isotype composition and avidity of naturally acquired anti-Plasmodium falciparum antibodies: differential patterns in clinically immune Africans and Amazonian patients. Am J Trop Med Hyg 1996;55:315-323.
148. Jakobsen PH, et al. Anti-phospholipid antibodies in patients with Plasmodium falciparum malaria. Immunology 1993;79:653-657.
149. Giha HA, et al. Nine-year longitudinal study of antibodies to variant antigens on the surface of Plasmodium falciparum-infected erythrocytes. Infect Immun 1999;67:4092-4098.
150. Brown AE, Webster HK, Lyon JA, Thomas AW, Permpanich B, Gross M. Characterization of naturally acquired antibody responses to a recombinant fragment from the N-terminus of Plasmodium falciparum glycoprotein 195. Am J Trop Med Hyg 1991;45:567-573.
151. Cavanagh DR, et al. A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol 1998;161:347-359.
152. Fruh K, et al. Human antibody response to the major merozoite surface antigen of Plasmodium falciparum is strain specific and short-lived. Infect Immun 1991;59:1319-1324.
153. Dodoo D, et al. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein I in Ghanaian children are not associated with protection from clinical malaria. Infect Immun 1999;67:2131-2137.
154. Perraut R, et al. Seasonal fluctuation of antibody levels to Plasmodium falciparum parasitized red blood cell-associated antigens in two Senegalese villages with different transmission conditions. Am J Trop Med Hyg 2000;62:746-751.
155. Jouin H, Rogier C, Trape JF, Mercereau-Puijalon O. Fixed, epitope-specific, cytophilic antibody response to the polymorphic block 2 domain of the Plasmodium falciparum merozoite surface antigen MSP-1 in humans living in a malaria-endemic area. Eur J Immunol 2001;31:539-550.
156. Sergent E, Parrot L. [Premunition in bovine piroplasmosis and human malaria]. Arch Inst Pasteur Alger 1951;29:117-119.
157. Bate CA, Taverne J, Dave A, Playfair JH. Malaria exoantigens induce T-independent antibody that blocks their ability to induce TNF. Immunology 1990;70:315-320.
158. Bate CA, et al. Antibodies against phosphatidylinositol and inositol monophosphate specifically inhibit tumour necrosis factor induction by malaria exoantigens. Immunology 1992;76:35-41.
159. Bate CA, Taverne J, Kwiatkowski D, Playfair JH. Phospholipids coupled to a carrier induce IgG antibody that blocks tumour necrosis factor induction by toxic malaria antigens. Immunology 1993;79:138-145.
160. de Souza JB, Todd J, Krishegowda G, Gowda DC, Kwiatkowski D, Riley EM. Prevalence and boosting of antibodies to Plasmodium falciparum glycosylphosphatidylinositols and evaluation of their association with protection from mild and severe clinical malaria. Infect Immun 2002;70:5045-5051.
161. Boutlis CS, et al. Antibodies to Plasmodium falciparum glycosylphosphatidylinositols: inverse association with tolerance of parasitemia in Papua New Guinean children and adults. Infect Immun 2002;70:5052-5057.
162. Ochsenbein AF, et al. A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. Proc Natl Acad Sci USA 1999;96:9293-9298.
163. Riley EM. The role of MHC- and non-MHC-associated genes in determining the human immune response to malaria antigens. Parasitology 1996;112:S39-S51.
164. Fazekas de St Groth B, Webster RG. Disquisitions of original antigenic sin. I. Evidence in man. J Exp Med 1966;124:331-345.
165. Sano G, Hafalla JC, Morrot A, Abe R, Lafaille JJ, Zavala F. Swift development of protective effector functions in naive CD8(+) T cells against malaria liver stages. J Exp Med 2001;194:173-180.
166. McGregor IA, Barr M. Antibody response to tetanus toxoid inoculation in malarious and non-malarious Gambian children. Trans R Soc Trop Med Hyg 1962;56:364-367.
167. Barr M, McGregor IA. Diphtheria antitoxin levels in the serum of Gambian Africans. Trans R Soc Trop Med Hyg 1962;56:368-370.
168. Greenwood BM, Bradley-Moore AM, Bryceson AD, Palit A. Immunosuppression in children with malaria. Lancet 1972;1:169-172.
169. Weidanz WP. Malaria and alterations in immune reactivity. Br Med Bull 1982;38:167-172.
170. Nussenzweig RS. Parasitic disease as a cause of immunosuppression. N Engl J Med 1982;306:423-424.
171. Troye-Blomberg M, Perlmann P. T cell functions in Plasmodium folciparum and other malarias. Prog Allergy 1988;41:253-287.
172. Achtman AH, Khan M, MacLennan IC, Langhorne J. Plasmodium chabaudi chabaudi infection in mice induces strong B cell responses and striking but temporary changes in splenic cell distribution. J Immunol 2003;171:317-324.
173. Urban BC, et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 1999;400:73-77.
174. Urban BC, Willcox N, Roberts DJ. A role for CDS 6 in the regulation of dendritic cell function. Proc Nad Acad Sci USA 2001;98:8750-8755.
175. Urban BC, et al. Peripheral blood dendritic cells in children with acute Plasmodium folciparum malaria. Blood 2001;98:2859-2861.
176. Ocana-Morgner C, Mota MM, Rodriguez A. Malaria blood stage suppression of liver stage immunity by dendritic cells. J Exp Med 2003;197:143-151.
177. Seixas E, Cross C, Quin S, Langhorne J. Direct activation of dendritic cells by the malaria parasite, Plasmodium chabaudi chabaudi. Eur J Immunol 2001;31:2970-2978.
178. Luyendyk J, Olivas OR, Ginger LA, Avery AC. Antigen-presenting cell function during Plasmodium yoelii infection. Infect Immun 2002;70:2941-2949.
179. Toure-Balde A, et al. Plasmodium falciparum induces apoptosis in human mononuclear cells. Infect Immun 1996;64:744-750.
180. Balde AT, Aribot G, Tall A, Spiegel A, Roussilhon C. Apoptosis modulation in mononuclear cells recovered from individuals exposed to Plasmodium falciparum infection. Parasite Immunol 2000;22:307-318.
181. Kemp K, et al. Cytokine production and apoptosis among T cells from patients under treatment for Plasmodium falciparum malaria. Clin Exp Immunol 2002;127:151-157.
182. Riccio EK, et al. Malaria associated apoptosis is not significantly correlated with either parasitemia or the number of previous malaria attacks. Parasitol Res 2003;90:9-18.
183. Kern P, Dietrich M, Hemmer C, Wellinghausen N. Increased levels of soluble Fas ligand in serum in Plasmodium falciparum malaria. Infect Immun 2000;68:3061-3063.
184. + T cells adoptively transferred into recipient mice after challenge with homologous parasite. Proc Natl Acad Sci USA 1998;95:1715-1720.
185. Wipasa J, Xu H, Stowers A, Good MF. Apoptotic deletion of Th cells specific for the 19-kDa carboxyl-terminal fragment of merozoite surface protein 1 during malaria infection. J Immunol 2001;166:3903-3909.
186. + T cells undergo extensive apoptosis during a Plasmodium chabaudi chabaudi AS infection. Parasite Immunol 2001;23:617-626.
187. Omer FM, de Souza JB, Riley EM. Differential induction of TGF-beta regulates proinflammatory cytokine production and determines the outcome of lethal and nonlethal Plasmodium yoelii infections. J Immunol 2003;171:5430-5436.